The FDA has delayed approval of GlaxoSmithKline and SkyePharma's reformulated Requip XL (ropinirole) as a treatment for Parkinson's disease. ...
Following the approvable letter for Requip XL issued in December 2007, GlaxoSmithKline submitted a response to the FDA. A final decision from the FDA had ...
5, 2008 (Thomson Financial delivered by Newstex) -- GlaxoSmithKline (NYSE:GSK) PLC's Requip XL has been delayed again by the FDA because the regulatory ...
The UK drugmaker that develops longer-lasting versions of older medicines for GlaxoSmithKline Plc said US regulators delayed final approval of Requip XL, ...
Requip and Mirapex are the two drugs most commonly used to treat RLS, and Albino said they work well, with about 90 percent of patients finding relief from ...
By Andrew Jack in London US regulators have delayed approval of Requip XL, a reformulated drug for Parkinsons’s disease, in a blow to GlaxoSmithKline and ...
all 8 news articles
Whether that means railing against newfangled pharmaceuticals (in a bit called “Requip”) or his celebrity double (“Screech”), or simply telling hecklers ...
That is what happened when Requip was approved for use in Restless Leg Syndrome and it seems to be happening with fibromyalgia now. On the other hand, ...
... including AstraZeneca's (AZN; S&P investment rank, 4 STARS, buy) Casodex (oncology), and GlaxoSmithKline's (GSK; 4 STARS) Requip (Parkinson's disease). ...